PE consortium makes $4.6b take-private bid for China Biologic
Centurium Capital, CITIC Capital and Hillhouse Capital are part of an investor group targeting a $4.6 billion take-private of China Biologic – just over a year after committing new equity to the US-listed company to protect it from other would-be acquirers.
The three private equity firms, together with Temasek Holdings, Parfield International and Hong Kong-listed medical device manufacturer PW Medtech Group, are offering to buy all outstanding shares in China...
More on Greater China
Latest News
Prosus leads $30m Series C for India agtech start-up
Prosus Ventures, formerly a VC arm of South African media conglomerate Naspers, has led a $30 million Series C round for Indian agricultural technology provider DeHaat.
Fund focus: Endiya sees India’s early-stage upside
Having scaled up in fund size to $75 million for its second vintage, Endiya Partners is looking for opportunities in an increasingly attractive yet competitive Indian start-up ecosystem
Monument Group recruits Japan representative
Placement agent Monument Group has appointed Hiroshi Nishimuro, formerly of Morgan Stanley, as its Japan representative to lead fundraising efforts and manage GP relationships in the country.
Pathway promotes head of Hong Kong office
Simon Lau, who has led the Asian operations at fund-of-funds Pathway Capital Management since 2012, has been promoted to managing director.